Nivolumab is a medication used to manage and treat metastatic melanoma and several other tumors. It is a monoclonal antibody that targets the anti-PD1 receptor, an immune checkpoint. This activity outlines the indications, mechanism of action, and administration for nivolumab to manage advanced cancers. This activity will also highlight the dosing, monitoring, and adverse event profile, factor of paramount importance for the multidisciplinary healthcare team in treating patients with metastatic melanoma and related conditions.

**Objectives:**
- Describe the mechanism of action of nivolumab in the immune-checkpoint blockade.
- Outline the indications for oncologic therapy with nivolumab. 
- Identify the most common adverse events associated with nivolumab therapy.
- Summarize some interprofessional team strategies that can be employed to ensure optimal outcomes for patients who can benefit from medication therapy using nivolumab.